The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series

Preventive Medicine

Volumn 61, Issue , 2014, Pages 20-25

  Harper, Diane M ^b   Verdenius, Inge ^a   Harris, George D ^b   Barnett, Angela L ^b   Rosemergey, Beth E ^b   Arey, Anne M ^b   Wall, Jeffrey ^b   Malnar, Gerard J ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compliance; Economic incentive; Health insurance; HPV4 vaccine; Payor source

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; DRUG SAFETY; FEMALE; HEALTH CARE SYSTEM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; POPULATION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES; VACCINATION; YOUNG ADULT; CHI SQUARE DISTRIBUTION; COMMUNITY CARE; COST; ECONOMICS; ETHNOLOGY; GOVERNMENT; HEALTH BEHAVIOR; IMMUNIZATION; INSURANCE; MEDICALLY UNINSURED; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTIONS; PATIENT COMPLIANCE; PREGNANCY; PREVENTIVE HEALTH SERVICE; PROGRAM EVALUATION; STATISTICS AND NUMERICAL DATA; TIME; VULNERABLE POPULATION;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; CHILD; DEDUCTIBLES AND COINSURANCE; FEMALE; HEALTH BEHAVIOR; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INSURANCE COVERAGE; MEDICALLY UNINSURED; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT COMPLIANCE; PREGNANCY; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; STATE GOVERNMENT; TIME FACTORS; UNCOMPENSATED CARE; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84893661751     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2014.01.007     Document Type: Article

References (45)

1. Anderson R.M., Aday L.A. Revisiting the behavioral model and access to medical care: does it matter?. J. Health Soc. Behav. 1995, 36:1-10.
2. Centers for Disease Control and Prevention Vaccines for Children (Available from: http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1011-1-hpv.pdf and http://www.immunizationmanagers.org/pdfs/Funding_Allocation.pdf Accessed June 30, 2013.
3. Centers for Disease Control and Prevention National and state vaccination coverage among adolescents aged 13 through 17years - United States, 2011. MMWR 2012, 61:671-677.
4. Centers for Disease Control and Prevention Adult vaccination coverage - United States, 2010. MMWR 2012, 61:66-72.
5. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin. Proc. 2009, 84(10):864-870.
6. Chou B., Krill L.S., Horton B.B., Barat C.E., Trimble C.L. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet. Gynecol. 2011, 118(1):14-20.
7. Cook R.L., Zhang J., Mullins J., et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J. Adolesc. Health 2010, 47(6):596-599.
8. Dempsey A., Cohn L., Dalton V., Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010, 28(4):989-995.
9. Dempsey A., Cohn L., Dalton V., Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26year old women. Vaccine 2011, 29(3):528-534.
10. Dobson S.R., McNeil S., Dionne M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309(17):1793-1802.
11. Dorell C.G., Yankey D., Santibanez T.A., Markowitz L.E. Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics 2011, 128(5):830-839.
12. Dorell C., Stokley S., Yankey D., Jeyarajah J., MacNeil J., Markowitz L. National and state vaccination coverage among adolescents aged 13-17years - United States, 2011. MMWR 2012, 61(34):67-671.
13. Epstein D., Jiménez-Rubio D., Smith P.C., Suhrcke M. Social determinants of health: an economic perspective. Health Econ. 2009, 18:495-502.
14. Gold R., Naleway A.L., Jenkins L.L., et al. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev. Med. 2011, 52(6):456-458.
15. Harper D.M., Verdenius I., Ratnaraj F., et al. Quantifying clinical HPV4 dose inefficiencies in a safety net population. PLoS One 2013, 8(11):e77961. (Nov 6). 10.1371/journal.pone.0077961.
16. Hirth J.M., Tan A., Wilkinson G.S., Berenson A.B. Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer 2012, 118(22):5623-5629.
17. Kessels S.J., Marshall H.S., Watson M., Braunack-Mayer A.J., Reuzel R., Tooher R.L. Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012, 30(24):3546-3556.
18. Kreimer A.R., Rodriguez A.C., Hildesheim A., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J. Natl. Cancer Inst. 2011, 103(19):1444-1451.
19. Lagarde M., Haines A., Palmer N. The impact of conditional cash transfers on health outcomes and use of health services in low and middle income countries. Cochrane Database Syst. Rev. 2009, 4. (CD008137). 10.1002/14651858.CD008137.
20. Lehtinen M., Paavonen J., Wheeler C.M., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13(1):89-99.
21. Mantzari E., Vogt F., Marteau T.M. Using financial incentives to increase initial uptake and completion of HPV vaccinations: protocol for a randomised controlled trial. BMC Health Serv. Res. 2012, 12:301.
22. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007, 56(RR-2):1-24.
23. Marteau T., Ashcroft R., Oliver A. Using financial incentives to achieve healthy behavior. BMJ 2009, 338:b1415.
24. Munoz N., Kjaer S.K., Sigurdsson K., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 2010, 102(5):325-339.
25. Neubrand T.P., Breitkopf C.R., Rupp R., Breitkopf D., Rosenthal S.L. Factors associated with completion of the human papillomavirus vaccine series. Clin. pediatr. (Phila) 2009, 48(9):966-969.
26. Neuzil K.M., Canh do G., Thiem V.D., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011, 305(14):1424-1431.
27. Niccolai L.M., Mehta N.R., Hadler J.L. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am. J. Prev. Med. 2011, 41(4):428-433.
28. Paul-Ebhohimhen V., Avenell A. Systematic review of the use of financial incentives in treatments for obesity and overweight. Obes. Rev. 2008, 9(4):355-367.
29. Perkins R.B., Brogly S.B., Adams W.G., Freund K.M. Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J. Women's Health (Larchmt) 2012, 21(8):813-820.
30. Rouzier R., Giordanella J.P. Coverage and compliance of human papilloma virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J. Adolesc. Health 2010, 47(3):237-241.
31. Rubin R.F., Kuttab H.M., Rihani R.S., Reutzel T.J. Patient adherence to three dose completion of the quadrivalent human papillomavirus (HPV) vaccine in a private practice. J. Community Health 2012, 37(6):1145-1150.
32. Safaeian M., Porras C., Pan Y., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev. Res. 2013, 6(11):1242-1250.
33. Schluterman N.H., Terplan M., Lydecker A.D., Tracy J.K. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine 2011, 29(21):3767-3772.
34. Smith L.M., Brassard P., Kwong J.C., Deeks S.L., Ellis A.K., Lévesque L.E. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health 2011, 11:645.
35. Smolen K.K., Gelinas L., Franzen L., et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012, 30(24):3572-3579.
36. StatSoft STATISTICA (data analysis software system), version 9.1. www.statsoft.com 2010, (Inc.), (Accessed June 30, 2013).
37. Tan W., Viera A.J., Rowe-West B., Grimshaw A., Quinn B., Walter E. The HPV vaccine: are dosing recommendations being followed?. Vaccine 2011, 29(14):2548-2554.
38. Tavafian S.S. Predictors of cervical cancer screening: an application of health belief model. Topics on Cervical Cancer with an Advocacy for Prevention 2012, (InTech. http://www.intechopen.com/books/topics-on-cervical-cancer-with-anadvocacy-for-prevention/predictors-of-cervical-cancer-screening-an-application-of-health-belief-model. Accessed June 30 2013). R. Rajamanickam (Ed.).
39. Tiro J.A., Pruitt S.L., Bruce C.M., et al. Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine 2012, 30(13):2368-2375.
40. US FDA Vaccines, Blood & Biologics (Accessed June 30, 2013). http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm.
41. Verdenius I., Harper D.M., Harris G.D., et al. Predictors of three dose on-time ôcompliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest. PLoS ONE 2013, 8(8):e71295.
42. Widdice L.E., Bernstein D.I., Leonard A.C., Marsolo K.A., Kahn J.A. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011, 127(1):77-84.
43. World Health Organization Commission on the Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on the Social Determinants of Health,WHO Geneva 2008, (Available from: http://whqlibdoc.who.int/publications/2008/9789241563703_eng.pdf Accessed June 30, 2013.).
44. World Health Organization World Conference on Social Determinants of Health (update. http://www.who.int/sdhconference/declaration/Rio_political_declaration.pdf Accessed June 30, 2013.).
45. Zimmerman R.K., Nowalk M.P., Lin C.J., et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J. Women's Health 2010, 19(8):1441-1447.